Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
- 26 September 2018
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (3) , 638-647
Abstract
Effective therapies for relapsed/refractory meningioma after surgery and radiation therapy represent an unmet need. Most meningiomas are highly vascularized tumors and, therefore, potentially amenable to antiangiogenic therapy. Herein, we review comprehensively the scientific literature on systemic therapy options for relapsed, persistent or metastatic meningioma, not amenable to local therapy. Also, this review offers insights into the function of vascular endothelial growth factor/receptor pathway both in health and disease. Further, we address the current status of the preclinical and clinical studies targeting vascular endothelial growth factor/receptor signaling in meningioma. Most relevant publications were identified through searching the PubMed/Medline database for articles published from inception to 1 February 2018. Vascular endothelial growth factor pathway activation might represent the primary driver of angiogenesis in meningioma. Positive findings of two prospective phase II trials, supported by the results of several retrospective cohorts, suggest a clinical benefit for the vascular endothelial growth factor inhibitor bevacizumab in refractory meningioma. Bevacizumab causes both peritumoral brain edema reduction and true meningioma shrinkage. Patients with WHO grades II–III meningioma appear to benefit more than patients with grade I disease. Similarly, responses have been documented with certain oral targeted anti-vascular endothelial growth factor/receptor agents. Further exploration of the role of vascular endothelial growth factor/receptor inhibitors in refractory meningioma seems warranted.Keywords
This publication has 53 references indexed in Scilit:
- Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 PatientsPLOS ONE, 2013
- Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approachesClinical Neuropathology, 2012
- Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective seriesJournal of Neuro-Oncology, 2012
- Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edemaAPMIS, 2011
- Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumabAnnals of Oncology, 2011
- Bevacizumab-induced regression of anaplastic meningiomaAnnals of Oncology, 2010
- Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningiomaAnti-Cancer Drugs, 2003
- Descriptive epidemiology of primary brain and CNS tumors: Results from the Central Brain Tumor Registry of the United States, 1990-1994Neuro-Oncology, 1999
- A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group studyJournal of Neuro-Oncology, 1993
- Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristicsEuropean Journal of Cancer and Clinical Oncology, 1991